Breathe Well Live Well
|
MediciNova shares crash after lead asthma drug fails IIb trial
FierceBiotech MediciNova's ($MNOV) shares crashed after the San Diego-based biotech said its Phase IIb study of an acute asthma drug failed to hit the primary endpoint. And while the CEO tried to put the data in context, offering reasons for optimism for a planned … MediciNova asthma drug fails trial; shares crash MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma … |
View full post on asthma – Google News
|
Rigel raises $130M for PhII trial of asthma drug
FierceBiotech Pfizer's decision to cut all allergy and respiratory drug development work came as good news for Rigel Pharmaceuticals, even though it meant the end of the two developers' pact for allergic asthma drug candidate R343. Pfizer bought into Rigel's … |
View full post on asthma – Google News
|
Pfizer returns allergic asthma drug to Rigel
FierceBiotech Pfizer's decision to ends its allergy and respiratory R&D work has prompted the company return rights to the R343 program for allergic asthma to Rigel Pharmaceuticals. The drug has shown promise in Phase I trials and Rigel plans to begin designing a … Rigel says Pfizer returns asthma therapy rights Rigel Assumes Development Responsibility for Inhaled Asthma Therapy Pfizer Hands Back Rigel Drug |
View full post on asthma – Google News